Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
MoonLake Immunotherapeutics | Director, 10%+ Owner | Class A Ordinary Shares, $0.0001 par value | 1.29M | $64.4M | $50.00 | Oct 4, 2024 | Direct |
Kymera Therapeutics, Inc. | Director, Other* | Common Stock, $0.0001 par value | 295K | $13.7M | $46.41 | Aug 20, 2024 | Direct |
Verastem, Inc. | 10%+ Owner | Common Stock | 994K | $10.9M | $10.95 | Jan 25, 2022 | Direct |
Olema Pharmaceuticals, Inc. | Director, 10%+ Owner | Common stock, $0.0001 par value | 524K | $7.78M | $14.85 | Jun 14, 2024 | Direct |
Merus N.V. | 10%+ Owner | Common Shares, (euro)0.09 nominal value per share | 233K | $6.47M | $27.79 | Oct 8, 2021 | Direct |
Kymera Therapeutics, Inc. | Director, Other* | Pre-Funded Warrants to Purchase Common Stock | 157K | $6.39M | $40.75 | Aug 20, 2024 | Direct |
ESSA Pharma Inc. | 10%+ Owner | Common Stock | 357K | $3.58M | $10.01 | Jul 11, 2022 | Direct |
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Pre-funded Warrants to Purchase Common Stock | 839K | $3.06M | $3.65 | Oct 29, 2024 | Direct |
Repare Therapeutics Inc. | 10%+ Owner | Common Shares, no par value | 549K | $2.96M | $5.38 | Nov 16, 2023 | Direct |
Third Harmonic Bio, Inc. | Other* | Common Stock | 177K | $2.53M | $14.30 | Oct 29, 2024 | Direct |
Allakos Inc. | 10%+ Owner | Common Stock, $0.001 par value | 855K | $2.14M | $2.50 | Jan 16, 2024 | Direct |
XOMA Corp | Director, Other*, 10%+ Owner | Common Stock, $0.0075 par value per share | 75.3K | $1.65M | $21.98 | May 17, 2023 | Direct |
Olema Pharmaceuticals, Inc. | Director, 10%+ Owner | Common stock, $0.0001 par value | 99.6K | $1.48M | $14.85 | Jun 14, 2024 | Indirect |
4D Molecular Therapeutics, Inc. | Other* | Common Stock, $0.0001 par value | 87.9K | $1.44M | $16.33 | Nov 8, 2024 | Direct |
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Common Stock, $0.001 par value | 220K | $988K | $4.48 | Oct 29, 2024 | Direct |
Cullinan Oncology, Inc. | 10%+ Owner | Common Stock | 64.2K | $799K | $12.46 | Jan 19, 2023 | Direct |
PIERIS PHARMACEUTICALS, INC. | 10%+ Owner | Common Stock, $0.001 par value | 745K | $633K | $0.85 | May 11, 2023 | Direct |
XOMA Corp | Director, Other*, 10%+ Owner | Common Stock, $0.0075 par value per share | 11.8K | $259K | $21.98 | May 17, 2023 | Indirect |
Rain Oncology Inc. | Director, Other* | Common Stock, $0.001 par value | 0 | $0 | $1.21 | Jan 25, 2024 | Direct |
MoonLake Immunotherapeutics | Director, 10%+ Owner | Class A Ordinary Shares, $0.0001 par value | 1.42M | Jun 6, 2024 | Direct | ||
Structure Therapeutics Inc. | 10%+ Owner | Convertible Non-Voting Ordinary Shares | 463K | May 10, 2023 | Direct | ||
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Warrants to Purchase Common Stock | 252K | Oct 29, 2024 | Direct | ||
4D Molecular Therapeutics, Inc. | Other* | Pre-Funded Warrant | 240K | Nov 8, 2024 | Direct | ||
XOMA Corp | Director, Other*, 10%+ Owner | 8.625% Series A Cumulative Perpetual Preferred Stock | 200K | May 17, 2023 | Indirect | ||
enGene Holdings Inc. | 10%+ Owner | Class A Common Shares | 104K | Oct 31, 2023 | Direct | ||
Cullinan Oncology, Inc. | 10%+ Owner | Series A Convertible Preferred Stock | 30K | Jan 19, 2023 | Direct | ||
Olema Pharmaceuticals, Inc. | Director, 10%+ Owner | Stock Option (Right to buy) | 23K | Jun 14, 2024 | Indirect | ||
Kymera Therapeutics, Inc. | Director, Other* | Stock Option (Right to Buy) | 12K | Aug 20, 2024 | Indirect | ||
MoonLake Immunotherapeutics | Director, 10%+ Owner | Option to Buy | 11.3K | Oct 4, 2024 | Indirect | ||
XOMA Corp | Director, Other*, 10%+ Owner | Non-Qualified Stock Option (right to buy) | 11K | May 17, 2023 | Indirect | ||
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Series X1 Convertible Preferred | 7.64K | Oct 29, 2024 | Direct | ||
XOMA Corp | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 772 | May 17, 2023 | Indirect | ||
XOMA Corp | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 412 | May 17, 2023 | Direct | ||
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Series X Convertible Preferred | 346 | Oct 29, 2024 | Direct | ||
Eledon Pharmaceuticals, Inc. | 10%+ Owner | Warrants to Purchase Series X1 Convertible Preferred Stock | 189 | Oct 29, 2024 | Direct | ||
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Common Stock, par value $0.001 | 0 | $9.10 | Jun 26, 2023 | Direct | |
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Common Stock, par value $0.001 | 0 | $9.10 | Jun 26, 2023 | Indirect | |
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X1 Convertible Preferred Stock | 0 | Jun 26, 2023 | Direct | ||
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 0 | Jun 26, 2023 | Direct | ||
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Series X Convertible Preferred Stock | 0 | Jun 26, 2023 | Indirect | ||
CTI BIOPHARMA CORP | Director, Other*, 10%+ Owner | Stock Option (Right to Buy) | 0 | Jun 26, 2023 | Indirect | ||
POINT Biopharma Global Inc. | Former 10% Owner | Common Stock, $0.0001 par value | 0 | $12.45 | Dec 18, 2023 | Direct | |
Rain Oncology Inc. | Director, Other* | Non-Voting Common Stock, $0.001 par value | 0 | Jan 25, 2024 | Direct | ||
Rain Oncology Inc. | Director, Other* | Stock Option (Right to Buy) | 0 | Jan 26, 2024 | Indirect | ||
Structure Therapeutics Inc. | 10%+ Owner | Ordinary Shares, $0.0001 par value per share | 0 | May 10, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FDMT | 4D Molecular Therapeutics, Inc. | Nov 8, 2024 | 6 | $0 | 4 | Nov 13, 2024 | Other* |
THRD | Third Harmonic Bio, Inc. | Oct 29, 2024 | 3 | -$14.3M | 4 | Oct 31, 2024 | Other* |
ELDN | Eledon Pharmaceuticals, Inc. | Oct 29, 2024 | 3 | $17.3M | 4 | Oct 31, 2024 | 10%+ Owner |
MLTX | MoonLake Immunotherapeutics | Oct 4, 2024 | 3 | -$100M | 4 | Oct 8, 2024 | Director, 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Aug 20, 2024 | 2 | $14.6M | 4 | Aug 22, 2024 | Director, Other* |
FDMT | 4D Molecular Therapeutics, Inc. | Jul 22, 2024 | 0 | $0 | 3 | Aug 1, 2024 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jun 18, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director, Other* |
OLMA | Olema Pharmaceuticals, Inc. | Jun 14, 2024 | 1 | $0 | 4 | Jun 18, 2024 | Director, 10%+ Owner |
MLTX | MoonLake Immunotherapeutics | Jun 6, 2024 | 1 | $0 | 4 | Jun 10, 2024 | Director, 10%+ Owner |
ELDN | Eledon Pharmaceuticals, Inc. | May 9, 2024 | 6 | $0 | 4 | May 13, 2024 | 10%+ Owner |
RAIN | Rain Oncology Inc. | Jan 25, 2024 | 8 | $0 | 4 | Jan 29, 2024 | Director, Other* |
ALLK | Allakos Inc. | Jan 16, 2024 | 0 | $0 | 3 | Jan 26, 2024 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jan 5, 2024 | 3 | $24.7M | 4 | Jan 9, 2024 | Director, Other* |
PNT | POINT Biopharma Global Inc. | Dec 18, 2023 | 3 | -$214M | 4 | Dec 20, 2023 | Former 10% Owner |
RPTX | Repare Therapeutics Inc. | Nov 15, 2023 | 6 | $6.25M | 4 | Nov 17, 2023 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Nov 2, 2023 | 6 | $5.3M | 4 | Nov 6, 2023 | Director, Other* |
PNT | POINT Biopharma Global Inc. | Nov 2, 2023 | 0 | $0 | 3 | Nov 6, 2023 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Nov 2, 2023 | 3 | $2.82M | 4 | Nov 3, 2023 | 10%+ Owner |
ENGN | enGene Holdings Inc. | Oct 31, 2023 | 0 | $0 | 3 | Nov 13, 2023 | 10%+ Owner |
OLMA | Olema Pharmaceuticals, Inc. | Sep 12, 2023 | 4 | $14.8M | 4 | Sep 14, 2023 | Director, 10%+ Owner |
CTIC | CTI BIOPHARMA CORP | Jun 26, 2023 | 18 | -$80.6M | 4 | Jun 28, 2023 | Director, Other*, 10%+ Owner |
OLMA | Olema Pharmaceuticals, Inc. | Jun 16, 2023 | 1 | $0 | 4 | Jun 21, 2023 | Director, 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jun 15, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director, Other* |
MLTX | MoonLake Immunotherapeutics | Jun 8, 2023 | 1 | $0 | 4 | Jun 12, 2023 | Director, 10%+ Owner |
XOMA | XOMA Corp | May 17, 2023 | 1 | $0 | 4 | May 19, 2023 | Director, Other*, 10%+ Owner |
PIRS | PIERIS PHARMACEUTICALS, INC. | May 11, 2023 | 0 | $0 | 3 | May 22, 2023 | 10%+ Owner |
GPCR | Structure Therapeutics Inc. | May 10, 2023 | 6 | $0 | 4 | May 12, 2023 | 10%+ Owner |
ELDN | Eledon Pharmaceuticals, Inc. | May 5, 2023 | 9 | $0 | 4 | May 9, 2023 | 10%+ Owner |
CTIC | CTI BIOPHARMA CORP | Apr 5, 2023 | 1 | $0 | 4 | Apr 7, 2023 | Director, Other*, 10%+ Owner |
GPCR | Structure Therapeutics Inc. | Feb 3, 2023 | 0 | $0 | 3 | Feb 13, 2023 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Jan 19, 2023 | 6 | $0 | 4 | Jan 19, 2023 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jan 11, 2023 | 4 | $1.25M | 4 | Jan 13, 2023 | Director, Other* |
XOMA | XOMA Corp | Jan 5, 2023 | 4 | $421K | 4 | Jan 9, 2023 | Director, Other*, 10%+ Owner |
THRD | Third Harmonic Bio, Inc. | Dec 20, 2022 | 3 | $879K | 4 | Dec 22, 2022 | 10%+ Owner |
THRD | Third Harmonic Bio, Inc. | Dec 19, 2022 | 0 | $0 | 3 | Dec 22, 2022 | 10%+ Owner |
RAIN | Rain Therapeutics Inc. | Nov 8, 2022 | 3 | $9.97M | 4 | Nov 10, 2022 | Director, Other*, 10%+ Owner |
XOMA | XOMA Corp | Sep 23, 2022 | 6 | $409K | 4 | Sep 27, 2022 | Director, Other*, 10%+ Owner |
XOMA | XOMA Corp | Sep 14, 2022 | 4 | $991K | 4 | Sep 16, 2022 | Director, Other*, 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Aug 22, 2022 | 3 | $14.2M | 4 | Aug 23, 2022 | Director, Other* |
CTIC | CTI BIOPHARMA CORP | Aug 9, 2022 | 12 | -$52M | 4 | Aug 11, 2022 | Director, Other*, 10%+ Owner |
EPIX | ESSA Pharma Inc. | Jul 11, 2022 | 0 | $0 | 3 | Jul 21, 2022 | 10%+ Owner |
FDMT | 4D Molecular Therapeutics, Inc. | Jun 16, 2022 | 0 | $0 | 3 | Jun 27, 2022 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director, Other* |
RPTX | Repare Therapeutics Inc. | Jun 13, 2022 | 3 | $1.9M | 4 | Jun 15, 2022 | 10%+ Owner |
OLMA | Olema Pharmaceuticals, Inc. | Jun 10, 2022 | 2 | $807K | 4 | Jun 14, 2022 | Director, 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jun 2, 2022 | 9 | $21.9M | 4 | Jun 6, 2022 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Jun 1, 2022 | 3 | $8.26M | 4 | Jun 3, 2022 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | May 26, 2022 | 6 | $4.15M | 4 | May 31, 2022 | Director, Other* |
KYMR | Kymera Therapeutics, Inc. | May 20, 2022 | 3 | $141K | 4 | May 24, 2022 | Director, Other* |
XOMA | XOMA Corp | May 18, 2022 | 1 | $0 | 4 | May 20, 2022 | Director, Other*, 10%+ Owner |
RPTX | Repare Therapeutics Inc. | May 18, 2022 | 3 | $3.57M | 4 | May 20, 2022 | 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | May 12, 2022 | 5 | $10.1M | 4 | May 16, 2022 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | May 5, 2022 | 6 | $4.87M | 4 | May 9, 2022 | Director, Other* |
MLTX | MoonLake Immunotherapeutics | Apr 5, 2022 | 0 | $0 | 3 | Apr 15, 2022 | Director, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Apr 1, 2022 | 2 | $2.97M | 4 | Apr 5, 2022 | 10%+ Owner |
CTIC | CTI BIOPHARMA CORP | Mar 9, 2022 | 1 | $0 | 4 | Mar 11, 2022 | Director, Other*, 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jan 27, 2022 | 4 | $5.08M | 4 | Jan 31, 2022 | Director, Other* |
VSTM | Verastem, Inc. | Jan 25, 2022 | 0 | $0 | 3 | Feb 7, 2022 | 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jan 24, 2022 | 2 | $10.3M | 4 | Jan 26, 2022 | Director, Other* |
ELDN | Eledon Pharmaceuticals, Inc. | Jan 20, 2022 | 0 | $0 | 3 | Jan 31, 2022 | 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Jan 19, 2022 | 3 | $14.1M | 4 | Jan 21, 2022 | 10%+ Owner |
RAIN | Rain Therapeutics Inc. | Jan 6, 2022 | 4 | $6.69M | 4 | Jan 10, 2022 | Director, Other*, 10%+ Owner |
CGEM | Cullinan Oncology, Inc. | Dec 31, 2021 | 0 | $0 | 3 | Jan 10, 2022 | 10%+ Owner |
OLMA | Olema Pharmaceuticals, Inc. | Nov 30, 2021 | 3 | $6.95M | 4 | Dec 2, 2021 | Director, 10%+ Owner |
RPTX | Repare Therapeutics Inc. | Oct 28, 2021 | 0 | $0 | 3 | Nov 8, 2021 | 10%+ Owner |
MRUS | Merus N.V. | Oct 7, 2021 | 6 | -$31.2M | 4 | Oct 8, 2021 | 10%+ Owner |
RAIN | Rain Therapeutics Inc. | Sep 21, 2021 | 3 | $154K | 4 | Sep 23, 2021 | Director, Other*, 10%+ Owner |
RAIN | Rain Therapeutics Inc. | Sep 13, 2021 | 3 | $6.47M | 4 | Sep 15, 2021 | Director, Other*, 10%+ Owner |
MRUS | Merus N.V. | Jul 2, 2021 | 3 | -$45.4M | 4 | Jul 7, 2021 | 10%+ Owner |
RAIN | Rain Therapeutics Inc. | Jul 1, 2021 | 6 | $9.08M | 4 | Jul 6, 2021 | Director, Other*, 10%+ Owner |
KYMR | Kymera Therapeutics, Inc. | Jul 1, 2021 | 3 | $25.6M | 4 | Jul 6, 2021 | Director, Other* |
KYMR | Kymera Therapeutics, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director, Other* |
RAIN | Rain Therapeutics Inc. | May 21, 2021 | 6 | $1.97M | 4 | May 25, 2021 | Director, Other*, 10%+ Owner |
XOMA | XOMA Corp | May 19, 2021 | 1 | $0 | 4 | May 21, 2021 | Director, Other*, 10%+ Owner |
RAIN | Rain Therapeutics Inc. | May 18, 2021 | 6 | $3.46M | 4 | May 20, 2021 | Director, Other* |
RAIN | Rain Therapeutics Inc. | May 13, 2021 | 3 | $827K | 4 | May 17, 2021 | Director, Other* |
RAIN | Rain Therapeutics Inc. | Apr 23, 2021 | 9 | $19.1M | 4/A | May 17, 2021 | Director, Other* |
OLMA | Olema Pharmaceuticals, Inc. | Mar 31, 2021 | 1 | $0 | 4 | May 26, 2021 | Director, 10%+ Owner |